Title: One-carbon metabolism-related compounds are associated with epigenetic aging biomarkers: Results from National Health and Nutrition Examination Survey (NHANES) 1999-2002

Authors: Anne Bozack,¹ Dennis Khodasevich,¹ Jamaji C. Nwanaji-Enwerem,² Nicole Gladish,¹ Hanyang Shen,¹ Saher Daredia,³ Mary Gamble,⁴ Belinda L. Needham,⁵ David H. Rehkopf,^{1,6,7,8,9} Andres $Cardenas^{1,8}$

Affiliations: 1. Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA, US

2. Department of Emergency Medicine, Center for Health Justice, and Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US

3. Department of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, CA, US

4. Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, US

- 5. Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, US
- 6. Department of Health Policy, Stanford University, Palo Alto, CA, USA

7. Department of Medicine - Primary Care and Population Health, Stanford University, Palo Alto, CA, US

8. Department of Pediatrics, Stanford University, Palo Alto, CA, USA

9. Department of Sociology, Stanford University, Palo Alto, CA, USA

Sources of support: AKB is supported by the National Institutes of Health (NIH) grant K99ES035109. JNE and AC are supported by the NIH grant R01ES031259. This research was also supported by the National Institute on Minority Health and Health Disparities (R01MD011721, MPI: BLN and DHR; and R01MD016595). The funders had no role in the decision to publish, preparation, review, or approval of the manuscript.

Corresponding author: Anne K. Bozack; 1701 Page Mill Rd., Palo Alto, CA, 94304; abozack@stanford.edu

Abbreviations: ADM: adrenomedullin; B2M: β-2 microglobulin; BKMR: Bayesian Kernel Machine Regression; BMI: body mass index; BMIQ: beta mixture quantile; CI: confidence interval; CpG: cytosine-guanine dinucleotide; CRP: C-reactive protein; CVD: cardiovascular disease; DNAmTL: DNA methylation telomere length; DunedinPoAm: Dunedin Pace-of-Aging; EAD: epigenetic age deviation; Hcy: homocysteine; HHS: Department of Health and Human Services; GDF-15: growth differentiation factor 15; MAE: median absolute error; MMA: methylmalonic acid; NCHS: National Center for Health Statistics; NHANES: National Health and Nutrition Examination Survey; OCM: one-carbon metabolism; PAI-1: plasminogen activation inhibitor 1; PIR: poverty to family income ratio; QC: quality control; RBC: red blood cell; SAH: *S*-adenosylhomocysteine; SAM: *S*-adenosylmethionine; SD: standard deviation; TIMP-1: tissue inhibitor metalloproteinase 1; US: United States

1 **Abstract**

- 27 **Keywords:** one-carbon metabolism, epigenetic aging, DNA methylation, folate, homocysteine, vitamin
- 28 B12, National Health and Nutrition Examination Survey (NHANES)

29 **Background**

55 decline,¹⁸ particularly in groups with existing neurological disorders,^{19–21} and all-cause mortality,¹⁷ 56 although associations may vary by population due to differences in diet, age, and genetic factors.²² 57 In recent years, the study of aging and the healthspan has advanced with the development of 58 epigenetic aging biomarkers, also known as epigenetic clocks. These biomarkers leverage DNA 59 methylation levels at specific cytosine-guanine dinucleotides (CpG sites) that change with age. This 60 phenomenon has been leveraged to train epigenetic clocks as linear combinations of DNA methylation 61 levels at age-related CpGs. Epigenetic clocks can be broadly classified as predictors of chronological age 62 (*i.e.*, first-generation clocks), $2^{3,24}$ aging-related phenotypes and mortality risk (*i.e.*, second-generation 63 clocks),^{25–27} and rate-of-aging (*i.e.*, third generation clocks).²⁸ Epigenetic age deviation (EAD), or the 64 difference between epigenetic and chronological age, is strongly associated with cognitive impairment, 65 dementia, BMI, cancer, CVD, other morbidities, and all-cause mortality.^{29,30} Second generation clocks 66 — have proven to be particularly strong predictors of cancer, CVD, comorbidity, and time to death^{25,27} — 67 aging-related outcomes that may have etiologies related to OCM deficiencies. 68 Testing the relationship between markers of OCM and EAD can advance our understanding of 69 how nutritional factors and OCM function are related to complex aging- and disease-related processes and 70 can inform the application of epigenic aging biomarkers in research and clinical settings. In this study, we 71 aimed to investigate associations of OCM-related micronutrients and biomarkers with EAD among 72 participants in the National Health and Nutrition Examination Survey (NHANES), a nationally 73 representative sample of adults in the United States (US). Our study focused on concentrations of the B 74 vitamins folate and B12, Hcy, and MMA and seven epigenetic aging biomarkers (Horvath1, 23 Horvath2, 24 75 Hannum, ³¹ PhenoAge, ²⁵ GrimAge 2²⁶ DunedinPoAm, ²⁸ and DNA methylation telomere length 76 (DNAmTL)³²). We hypothesized that promoters of OCM (*i.e.*, folate and B12) would be associated with 77 lower EAD, whereas indicators of OCM deficiencies (*i.e.*, Hcy and MMA) would be associated with 78 increased EAD.

81 *Study population*

104 DNA methylation data were imported into R for preprocessing and quality control (QC). The

105 preprocessing and QC pipeline included color correction, background subtraction, and removal of outlier 106 samples based on median intensity values.

107 *Epigenetic age and biomarkers*

 108 Epigenetic age estimates and aging biomarkers were provided by NHANES.³⁵ Prior to biomarker 109 calculation, DNA methylation data were normalized using the beta mixture quantile (BMIQ) method, 110 which adjusts for probe type bias.³⁷ For the calculation of the Horvath1, Horvath2, PhenoAge, and 111 GrimAge2 clocks, a modified BMIQ method was applied using a gold standard based on the largest 112 training dataset in the Horvath1 clock.²³ The epigenetic age estimates or scores were calculated for each 113 participant using the respective published coefficients and intercepts. We focused on widely studied and 114 established epigenetic aging biomarkers including three first-generation clocks (*i.e.*, trained to estimate 115 chronological age): Horvath1,²³ Horvath2,²⁴ and Hannum;³¹ two second-generation clocks (*i.e.*, trained to 116 predict aging-related phenotypes, mortality, and morbidity risk): PhenoAge²⁵ and GrimAge2;²⁶ a third-117 generation clock (*i.e.*, trained to measure the rate of change of epigenetic age): Dunedin Pace-of-Aging 118 (DunedinPoAm);²⁸ and telomere length (DNAmTL).³² GrimAge2 is an updated version of the GrimAge 119 biomarker of mortality risk, which includes training on additional DNA methylation-based estimates of 120 plasma proteins (high sensitivity C-reactive protein (CRP) and hemoglobin A1C). Due to the high 121 correlation between GrimAge and GrimAge2 in NHANES (*r* = 0.99), we chose to only analyze 122 GrimAge2. In addition to GrimAge2 calculations, available NHANES data also includes DNA 123 methylation-based estimates of plasma proteins used in the calculation of this clock. 124 *Nutritional biochemistries*

125 Methods for nutritional biochemistries are described on the NHANES website with the respective 126 data releases.^{38,39} Briefly, serum folate and B12 concentrations were measured using the Quantaphase II 127 Folate/vitamin B12 radioassay kit (Bio-Rad Laboratories, Hercules, CA, US).³⁸ RBC folate was measured 128 by diluting samples in ascorbic acid in water and incubating or freezing to hemolyze RBCs. Samples were 129 diluted again in protein diluent and RBC folate was measured using methods analogous to serum folate. 130 Plasma Hcy was measured using the Abbott Homocysteine assay, a fluorescence polarization

131 immunoassay, and the Abbott IMX analyzer (Abbott Diagnostics, Chicago, IL, US). MMA was extracted 132 from plasma or serum with a strong anion exchange resin, and concentrations were measured by gas 133 chromatography and a mass selective detector.

134 *Covariates*

135 Demographic, socioeconomic, anthropometric measures, and self-reports of health-related 136 behaviors were collected as part of the NHANES questionnaire and physical examination. As defined by 137 NHANES, chronological age at the time of the screening interview was calculated from reported date of 138 birth. In the case of missing date of birth, reported age in years was used to impute date of birth. Self-139 reported race and ethnicity were classified as Non-Hispanic White, Mexican American, other Hispanic, 140 Non-Hispanic Black, or other race including Multiracial. Smoking status was based on the Smoking and 141 Tobacco Use Questionnaire Section and classified as never (not having smoked at least 100 cigarettes in 142 life), former (having smoked at least 100 cigarettes in life but not currently smoking), or current (having 143 smoked at least 100 cigarettes in life and currently smoking every day or some days). Alcohol intake in 144 average number of drinks per day in the last 12 months was calculated from the Alcohol Use 145 Questionnaire Section. Occupational status was obtained from the Occupation Questionnaire Section and 146 classified as white-collar and professional work, white-collar and semi-routine work, blue-collar and high-skill work, blue-collar and semi-routine work, or no work as described.⁴⁰ Education level was 148 classified as less than high school, high school diploma (including GED), or more than high school. The 149 poverty to family income ratio (PIR) was based on the Department of Health and Human Services' (HHS) 150 poverty guidelines and calculated as the family income divided by the poverty guidelines for family size 151 and year. Body mass index (BMI) in kg/m^2 was calculated from height and weight measurements 152 collected by trained technicians during examinations.

153 Data on selected protein concentrations measured in blood were also available in NHANES. 154 Serum β-2 microglobulin (B2M) concentrations were measured with a B2M immunoassay and serum 155 cystatin C concentrations were measured with a Cystatin C immunoassay on an automated multi-channel 156 analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, US).⁴¹ CRP concentrations were measured

157 using latex-enhanced nephelometry.^{42,43} Glycohemoglobin (hemoglobin A1C) concentrations in plasma 158 were measured using an HPLC-based automated glycohemoglobin analyzer (Primus, Kansas City, MO, 159 US).^{44,45}

160 *Statistical analyses*

161 Among 2,532 participants with epigenetic age estimates, we excluded those with a recorded age 162 of ≥85 years (*n* = 130) or with a mismatch between recorded sex and a DNA methylation-based sex 163 estimate (*n* = 56) (**Supplementary Figure 1**). We calculated epigenetic age deviation (EAD), also known 164 as epigenetic age acceleration,⁴⁶ as the residuals of regressing chronological age in years on epigenetic 165 age. DunedinPoAm was analyzed centered and scaled. Blood cell type proportions (CB8+ T cells, CD4+ 166 T cells, neutrophils, monocytes, B cells, and natural killer cells) were estimated using regression 167 calibration⁴⁷ based on IDOL probe selection.^{48,49}

168 Descriptive statistics before survey weighting were calculated as means and standard deviations 169 (SDs) for continuous variables and frequencies and proportions for categorical variables. We evaluated 170 performance of the epigenetic aging biomarkers by calculating correlations and median absolute errors 171 (MAEs) between chronological age and estimated epigenetic age. Survey weights were provided with the 172 NHANES epigenetic biomarkers dataset.³⁵ The survey design was specified using the *Survey* R package 173 for statistical analyses.^{50,51} To preserve the study design, the survey design was specified prior to dropping 174 participants ≥ 85 years old and sex mismatches. Correlations between OCM-related micronutrient 175 concentrations (serum folate, RBC folate, B12, Hcy, and MMA) were calculated using the *svycor* 176 function using the bootstrap procedure in the *jtools* R package.⁵² 177 We evaluated associations of OCM-related micronutrients and biomarkers with epigenetic aging 178 biomarkers (EAD residuals or DunedinPoAm) using survey-design weighted generalized linear regression 179 models. Analyses were conducted using the *svyglm* function in the *Survey* R package.^{50,51} The 180 concentrations of serum folate, RBC folate, B12, Hcy, and methylmalonic acid were log₂ transformed to 181 reduce the influence of outliers and meet model assumptions. Primary models were adjusted for potential

182 confounders and precision variables identified *a priori*: chronological age, chronological age², sex, race 183 and ethnicity, smoking status, education level, occupation, and PIR. 184 Smoking and alcohol intake may be associated with concentrations of OCM-related compounds 185 due to lifestyle and dietary factors. In addition, smoking⁵³ and alcohol⁵⁴ may act as folate antagonists by 186 affecting the absorption, metabolism, and maintenance of circulating levels. In our NHANES study 187 sample, we found that current smoking status compared to never smoking was negatively associated with 188 the concentrations of serum folate, RBC folate, and MMA and positively associated with the 189 concentration of Hcy ($p < 0.05$; **Supplemental Tables 1 and 2**), consistent with previous studies.^{55,56,56} 190 Alcohol intake was negatively associated with B12 concentration and positively associated with Hcy 191 concentration (*p* < 0.05). In addition, former and current smokers reported greater alcohol intake 192 (drinks/day, never smokers = 0.2; former smokers = 0.4; current smokers = 0.8; $p < 0.001$) 193 (**Supplemental Table 1**). Therefore, we also conducted analyses adjusting for smoking status (former or 194 current smoking vs. never) and alcohol intake to evaluate if associations of OCM-related compounds and 195 epigenetic aging biomarkers were independent of these exposures. When adjusting for smoking or alcohol 196 alone, we saw the largest change in effect sizes with inclusion of smoking in the model (data not shown), 197 and, consequently, we also tested for interactions between the concentrations of OCM-related compounds 198 and smoking status by conducting stratified analyses and including an interaction term in unstratified 199 analyses. 200 We further added log_2 -transformed cystatin C concentration, an indicator of renal function, as a 201 covariate to the models. Elevated homocysteine can impair renal function, and, in turn, impaired renal 202 function increases the risk of cardiovascular disease.⁵⁷ In addition, poor renal function has been associated 203 with increased serum folate and RBC folate concentration in a previous study in NHANES.⁵⁸

204 Considering conflicting evidence of the relationship between excess folate and B12 and adverse 205 health outcomes, including cancer progression and cognition,^{59–63} we tested for non-linear associations 206 using fully adjusted models with folate tertiles (serum folate: < 11.2 , ≥ 11.2 and < 17.6 , and ≥ 17.6 207 ng/mL; RBC folate: $\langle 250, \geq 250 \text{ and } \langle 352, \text{ and } \geq 352 \text{ ng/mL RBC} \rangle$ and B12 tertiles ($\langle 398, \geq 398 \text{ and } \langle 399, \rangle$

208 583, and \geq 583 pg/mL). We also conducted analyses with the dichotomous variable 209 hyperhomocysteinemia (Hcy concentration > 15 umol/L)⁶⁴ vs. not. 210 To evaluate if individual GrimAge2 components were contributing to the associations with 211 GrimAge2 EAD, we conducted adjusted analyses of serum folate, RBC folate, and homocysteine 212 concentrations using GrimAge2 components (plasma protein surrogates and smoking pack years) as the 213 outcomes. We conducted complementary analyses for proteins with laboratory measures, if available 214 (B2M, cystatin C, CRP, and hemoglobin A1C). 215 We performed sensitivity analyses adjusting for cell type proportions to distinguish between 216 intrinsic aging (*i.e.*, intracellular) and extrinsic aging (*i.e.*, reflecting age-related changes in cell type 217 proportions). Our primary analyses were conducted using complete cases. We also conducted sensitivity 218 analyses following imputation of missing covariate data. Data were imputed with multiple imputation by 219 chained equations using the *MICE* R package⁶⁵ and 5 iterations. Following imputation, we reanalyzed 220 associations of OCM-related micronutrients and compounds with aging biomarkers using fully adjusted 221 weighted generalized linear regression models and pooled estimates from each imputed dataset with the 222 *pool* function. 223 We used 95% confidence intervals (95% CIs) to evaluate precision of associations and *p* < 0.05 to 224 test for statistical significance. All analyses were conducted in R version 4.4.1.⁶⁶ We used the STROBE-225 nut checklist when writing our report. 67 226 227 **Results** 228 Epigenetic aging biomarker and nutritional biomarker data were available for 2,346 participants. 229 Participant demographic characteristics and concentrations of OCM-related nutrients and compounds, 230 prior to survey weighting, are shown in **Table 1**. Participants had a mean (SD) chronological age of 65.1 231 (9.3) years, and approximately half (51.2%) of participants were male. Nearly all participants were folate 232 replete; 5 participants had serum folate concentrations less than or equal to the reference value of 3 233 ng/mL.⁶⁸ Twenty-one (0.9%) participants were classified as B12 deficient (concentration <150 pg/mL)

234 and 329 (14.0%) were classified as B12 insufficient (concentration $<$ 300 pg/mL).⁸

- 235 Hyperhomocysteinemia was more common, with 192 (8.2%) participants having Hcy concentration > 15 236 umol/L. 64
- 237 Participant characteristics stratified by smoking status are shown in **Supplemental Table 1**. 238 Compared to never smokers, former smokers were more likely to be male and had greater alcohol intake, 239 lower median B12 concentration, and greater median Hcy concentration; current smokers were more 240 likely to be male and younger, and had lower BMI, greater alcohol intake, lower median concentration of 241 serum folate and RBC folate, and higher median concentration of Hcy. 242 All first- and second-generation clocks were strongly correlated with chronological age, with 243 Pearson correlation coefficients ranging from $r = 0.76$ for PhenoAge to $r = 0.87$ for Horvath2 ($p < 0.001$) 244 (**Supplemental Figure 2**). The Horvath2 clock had the lowest MAE compared to chronological age (2.71 245 years) whereas PhenoAge had the largest MAE (10.33 years). As expected, DunedinPoAm was very 246 weakly correlated with chronological age $(r = 0.04; p = 0.049)$ and DNAmTL was negatively correlated 247 with chronological age $(r = -0.58; p < 0.001)$. 248 After survey weighting, there were moderate correlations of serum folate with RBC folate and 249 Hcy with MMA (*r* = 0.51 and 0.50, respectively; *p* < 0.001) (**Supplemental Figure 3**). Serum folate was 250 significantly but weakly associated with B12 ($r = 0.04$; $p = 0.034$), Hcy ($r = -0.07$; $p = 0.002$), and MMA 251 $(r = 0.05; p = 0.014)$. There were also weak correlations of RBC folate with Hcy $(r = -0.09; p < 0.001)$ 252 and B12 with Hcy ($r = -0.05$; $p < 0.001$) and MMA ($r = -0.02$; $p < 0.001$). 253 *Associations of folate and B12 with epigenetic aging biomarkers* 254 **Figure 2** and **Supplementary Table 3** show results of our analyses of promoters of OCM (*i.e.*, 255 serum and RBC folate and B12). Our primary analyses used weighted generalized linear regression
- 256 models adjusted for chronological age, chronological age², sex, race and ethnicity, BMI, education level,
- 257 occupation, and PIR. We additionally adjusted for self-reported smoking status, alcohol intake, and
- 258 cystatin C, an indicator of renal function.

- 284 B12 concentration and tertiles were not significantly associated with any epigenetic aging
- 285 biomarker ($p > 0.05$).
- 286 *Associations of homocysteine and methylmalonic acid with epigenetic aging biomarkers*
- 287 Associations of markers of OCM deficiencies (*i.e.*, Hcy and MMA) with epigenetic aging
- 288 biomarkers are shown in **Figure 3** and **Supplementary Table 3**. Hcy concentration was positively
- 289 associated with PhenoAge EAD (*B* (95% CI) = 1.05 years per doubling (0.06, 2.04); $p = 0.039$),
- 290 GrimAge2 EAD (*B* (95% CI) = 1.93 years per doubling (1.16, 2.71); *p* < 0.001), and DunedinPoAm (*B*
- 291 (95% CI) = 0.26 SDs per doubling (0.10, 0.41); $p = 0.003$). After adjusting for smoking status and alcohol
- 292 intake, associations of Hcy with GrimAge2 EAD and DunedinPoAm remained significant but attenuated
- 293 (GrimAge2 EAD: *B* (95% CI) = 1.32 years per doubling (0.69, 1.94); *p* = 0.001 and DunedinPoAm: *B*
- 294 (95% CI) = 0.14 SDs per doubling (0.00, 0.27); $p = 0.048$). With cystatin C adjustment, the association
- 295 with GrimAge2 EAD was further attenuated (B (95% CI) = 0.82 years per doubling (0.05, 1.60); $p =$
- 296 0.040), and the association with DunedinPoAm was null. Hyperhomocysteinemia vs. normal Hcy range
- 297 was associated with greater PhenoAge EAD (B (95% CI) = 1.97 years (0.54, 3.40); $p = 0.012$) and
- 298 GrimAge2 EAD (*B* (95% CI) = 2.00 years (0.83, 3.17); *p* = 0.003) (**Supplemental Table 4**). In stratified
- 299 analyses, Hcy concentration was significantly and positively associated with GrimAge2 EAD among
- 300 former smokers (*B* (95% CI) = 1.47 years year doubling (0.47, 2.48); $p = 0.008$) and current smokers (*B*
- 301 (95% CI) = 1.76 years per doubling (0.50, 3.03); *p* = 0.010), but not among never smokers (*B* (95% CI) =
- 302 0.82 years per doubling (-0.11, 1.75); *p* = 0.08), with significant interaction between Hcy concentration
- 303 and former vs. never smoking $(p_{int} = 0.027)$ (**Figure 4** and **Supplemental Table 5**).
- 304 MMA concentration was not associated with the epigenetic aging biomarkers in our primary 305 analyses. However, among former smokers, MMA was positively associated with PhenoAge EAD (*B*
- 306 (95% CI) = 0.88 years per doubling (0.16, 1.60); $p = 0.021$).
- 307 *Associations with GrimAge2 components*

308 GrimAge2 is calculated as a weighted linear combination of DNA methylation-based surrogates 309 for 9 plasma proteins and smoking pack years. Therefore, to evaluate if individual components of

310 GrimAge2 were driving the associations of serum folate, RBC folate, and Hcy with GrimAge2 EAD, we 311 evaluated associations of each of the components separately. For serum folate concentration, only the 312 association with the surrogate for smoking pack years was significant, even after adjusting for self-313 reported smoking status (*Z*-score scale) (*B* (95% CI) = -0.07 per doubling (-0.13, -0.01); $p = 0.033$) 314 (**Table 2**). RBC folate concentration was significantly associated with GDF15 (*B* (95% CI) = 0.07 per 315 doubling (0.01, 0.03); $p = 0.023$), PAI1 (*B* (95% CI) = 0.14 per doubling (0.01, 0.27); $p = 0.038$), and 316 log(CRP) (*B* (95% CI) = 0.23 per doubling (0.11, 0.35); *p* = 0.002). Hcy concentration was positively 317 associated with five GrimAge2 components: B2M (*B* (95% CI) = 0.14 per doubling (0.06, 0.22); $p =$ 318 0.002), Cystatin C (*B* (95% CI) = 0.09 per doubling (0.02, 0.16); *p* = 0.021), TIMP1 (*B* (95% CI) = 0.08 319 per doubling (0.03, 0.13); *p* = 0.005), ADM (*B* (95% CI) = 0.17 per doubling (0.06, 0.29); *p* = 0.007), and 320 smoking pack years (*B* (95% CI) = 0.15 per doubling (0.02, 0.28); $p = 0.030$). 321 Laboratory measures for serum B2M and cystatin C concentrations, CRP concentration, and 322 hemoglobin A1C were also available in these NHANES cycles. Within our sample, all GrimAge2 323 components were moderately correlated with their measured counterparts (without survey weighting: 324 B2M: *r* = 0.25; cystatin C: *r* = 0.22; CRP: *r* = 0.28; hemoglobin A1C: *r* = 0.50; *p* < 0.001). Therefore, we 325 also tested if Hcy concentration was significantly associated with measured values (**Table 2**). Overall, 326 results were consistent with those of the GrimAge2 components. However, RBC folate concentration was 327 positively associated $log_2(cystatin C)$ (*B* (95% CI) = 0.11 per doubling (0.01, 0.21); $p = 0.029$) 328 Hcy concentration was also associated with lower log₂(hemoglobin A1C) (B (95% CI) = -0.04 per 329 doubling (0.06, 0.02)). 330 *Sensitivity analyses* 331 In sensitivity analyses adjusting for estimated cell type proportions, results were similar to those 332 of our primary analyses but attenuated (**Supplemental Table 6**). The association of Hcy concentration

333 with GrimAge2 EAD remained significant $(B (95\% \text{ CI}) = 1.13 \text{ years per doubling } (0.52, 1.75); p =$

334 0.007). Analyses using imputed covariate data were also largely consistent with our primary analyses

335 (**Supplemental Table 7**). A doubling in Hcy concentration was associated with 1-year greater PhenoAge

```
336 EAD (95% CI = 0.13, 1.87, p = 0.029), 1.44 years greater GrimAge2 EAD (95% CI = 0.87, 2.00, p
```

```
337 \leq 0.001, and 0.17 SD greater DunedinPoAm (95% CI = 0.04, 0.31, p = 0.019).
```
338

339 **Discussion**

340 We tested associations of OCM-related biomarkers with epigenetic aging biomarkers in 341 NHANES, a nationally representative sample of adults in the US where DNA methylation was assayed on 342 the population age 50 and older. The strongest and most robust associations were with EAD measured by 343 second generation clocks. We provide evidence that greater concentration of Hcy, an indicator of OCM 344 deficiencies, is associated with greater GrimAge2 EAD and DunedinPoAm. For each doubling of Hcy 345 concentration, GrimAge2 EAA was 1.32 years greater and DunedinPoAm was 0.14 SDs greater. This 346 association persisted after adjustment for smoking status and alcohol intake – folate antagonists and 347 behaviors associated with poor diet quality. We also found that serum folate concentration was 348 significantly associated with lower GrimAge2 EAD and DunedinPoAm and greater DNAmTL EAD; 349 however, associations were imprecise after adjusting for smoking status and alcohol intake. Similarly, the 350 association of Hcy concentration with greater PhenoAge EAD was attenuated after controlling for 351 smoking and alcohol. It is known that smoking and alcohol intake are associated with increased EAD, $69-71$ 352 and changes in OCM-related biomarkers may be one mechanism through which this occurs. 353 While our study did not directly investigate clinical endpoints, our findings support previous 354 research linking elevated Hcy to adverse age-related health outcomes, including cognitive impairment and 355 decline,¹⁸ cardiovascular disease incidence and¹⁷ mortality¹⁷ and all-cause mortality.¹⁷ Particularly 356 relevant to the current study, in NHANES 1999–2006, Hcy has been associated with increased all-cause 357 mortality and CVD mortality.⁷² GrimAge2 is an epigenetic clock developed to estimate mortality risk.²⁶ 358 GrimAge2 is calculated as the weighted linear combination of sex, age, and DNA methylation surrogates 359 for smoking pack years and 9 plasma proteins (adrenomedullin (ADM), B2M, cystatin C, growth 360 differentiation factor 15 (GDF-15), leptin, CRP, hemoglobin A1C, plasminogen activation inhibitor 1

361 (PAI-1), and tissue inhibitor metalloproteinase 1 (TIMP-1)). In addition to the overall positive association

362 of Hcy concentration and hyperhomocysteinemia with GrimAge2 EAD, we found that Hcy was 363 associated with greater DNA methylation surrogates of B2M (a biomarker of cardiovascular disease, 364 idney function, and inflammation⁷³), cystatin C (a biomarker of kidney function⁷⁴), TIMP1 (a regulator 365 of cell growth⁷⁵ and inflammation⁷⁶), ADM (a vasodilator and prognostic marker in CVD⁷⁷), and smoking 366 pack years. In addition, analyses of directly measured protein levels were consistent with our findings on 367 epigenetic estimates. In stratified analyses, we found evidence that Hcy has a stronger association with 368 GrimAge2 EAD among former and current smokers compared to never smokers. 369 DunedinPoAm is an epigenetic biomarker that estimates the rate of change of 18 biomarkers 370 capturing organ-system integrity and was trained on data over a 12-year span.²⁸ The biomarkers included 371 both blood biochemistries (*e.g.*, hemoglobin A1C, CRP, lipoprotein (a), HDL cholesterol) and functional 372 and cardiometabolic measurements (*e.g.*, BMI, cardiorespiratory fitness, pulmonary function). Greater 373 DunedinPoAm has been associated with greater physical and cognitive decline, morbidity, and 374 mortality.²⁸ In our study, Hcy was positively associated with DunedinPoAm and was robust to smoking 375 and alcohol adjustment. However, this association was null after adjustment for cystatin C, suggesting 376 that kidney function may be involved in the mechanism linking Hcy to DunedinPoAm. 377 We also found significant negative associations of serum folate with GrimAge2 EAD and 378 DunedinPoAm before adjusting for smoking and alcohol. After smoking and alcohol intake adjustment, 379 associations remained negative but did not reach statistical significance. Stratified analyses suggested that 380 folate may be protective against increased DunedinPoAm and GrimAge2 EAD among smokers, although 381 we did not find significant Hcy and smoking interaction. However, our analyses of smoking-specific 382 effects are limited by small sample size (*N* = 811 never smokers, *N* = 732 former smokers, and *N* = 287 383 current smokers with complete serum folate and complete covariate data). 384 In contrast to our hypothesis that higher folate concentration would be protective against 385 epigenetic aging, we observed a trend toward a positive association between RBC folate concentration 386 and epigenetic aging measured by second generation clocks and DunedinPoAm. Although these 387 associations did not reach statistical significance in the NHANES sample overall, associations of RBC

388 folate with GrimAge2 EAD and DunedinPoAm were positive and significant among former smokers. 389 Serum folate and RBC folate are both indicators of folate deficiency and were significantly correlated in 390 our study. Although RBC folate is reflective of long-term folate status, measurement of RBC folate is 391 more costly, has greater analytical variability, and has not shown diagnostic value in clinical settings 392 beyond that of serum folate concentrations.⁷⁸ We hypothesize that RBC folate concentration may also 393 capture pathophysiological changes beyond serum folate measurements. Red blood cell abnormalities, 394 including megaloblastic anemia, macrocytosis, and increased mean cell volume and red cell distribution 395 width, are associated with folate and B12 deficiencies.⁷⁹ However, cell distribution width has also been 396 positively associated with inflammatory markers and oxidative stress, $80,81$ and RBCs may be involved in 397 inflammatory processes due to their cytokine binding capacity.⁸² The second generation clocks and 398 DunedinPoAm are trained on biomarkers of inflammation, such as CRP (PhenoAge, GrimAge2, 399 DunedinPoAm), white blood cell count (DunedinPoAm), mean cell volume (PhenoAge), and red blood 400 cell distribution width (PhenoAge), and therefore these clocks may be sensitive to inflammatory-related 401 variations in RBCs. Furthermore, RBC folate concentration was positively associated with cystatin C, 402 both in our study and a previous analysis of NHANES.⁵⁸ The relationship between RBC folate and the 403 second-generation clocks may also be reflecting impaired renal function related in aging and chronic 404 disease development. These explanations are supported by our analyses of RBC folate concentration with 405 the GrimAge2 components and measured proteins related to inflammation and renal function. 406 Associations of plasma folate, B12, B6, and Hcy with Horvath1 EAD, PhenoAge EAD, and 407 GrimAge EAD have previously been investigated in the Veterans Affairs Normative Aging Study, a 408 cohort of older community-dwelling men $(N = 715)$.⁸³ This study used Bayesian Kernel Machine 409 Regression (BKMR), a mixture approach that allows for the selection of statistically important 410 independent variables. B6 was identified as important for predicting PhenoAge EAD with a negative 411 direction of association, and folate was identified as important for predicting GrimAge EAD and 412 PhenoAge EAD with positive directions of associations. Our findings were not consistent with these 413 results, possibly due to differences in populations studied and analytical differences. BKMR produces

414 single-exposure effect estimates holding all other exposures at a fixed percentile. Given the complex 415 relationship between nutritional factors and OCM metabolites, including an antagonistic relationship 416 between one-carbon donors and Hcy, it may be difficult to interpret effects of folate when B12, B6, and 417 Hcy are evaluated at a common percentile. 418 Associations of OCM-related compounds and epigenetic aging have also been analyzed in a 419 supplementation study among older adults with mild cognitive impairment (*N* = 217). This study reported 420 a positive correlation between baseline plasma Hcy and rate of aging (*i.e.*, epigenetic age divided by 421 chronological age) measured by Horvath2, Hannum, Zhang, 84 DunedinPACE, 85 and Index, a 422 commercially available epigenetic clock (Elysium Health, New York, NY, US).⁸⁶ Furthermore, this study 423 found evidence that supplementation with a B-vitamin complex (B6, B12, and folic acid) may decrease 424 epigenetic age among individuals with hyperhomocysteinemia. 425 Understanding the relationship between OCM-related compounds and epigenetic aging 426 biomarkers may help advance the study of nutrition and aging. Randomized controlled trials have 427 demonstrated that folic acid supplementation lowers homocysteine levels, $87,88$ particularly among 428 individuals with low baseline folate.⁸⁹ However, there is less evidence for the downstream health benefits 429 of supplementation with folic acid or other B vitamins. In a 7-year study of women with high risk of CVD 430 (*N* = 5,442), supplementation with folic acid, B6, and B12 did not significantly reduce the risk of 431 cardiovascular events compared to placebo, despite a significant reduction in homocysteine levels in the 432 treatment group.⁹⁰ Similarly, a 3-year study of adults with cerebral infarction ($N = 3,680$) found no

433 association of supplementation with folic acid, B6, and B12 with risk of stroke, although lower Hcy was

434 associated with reduced risk of coronary heart disease events.⁹¹ Meta-analyses of folic acid trials

435 concluded that supplementation may reduce the risk of stroke but not mortality⁹², and that reductions in

436 CVD were greatest among individuals with low baseline folate and high reductions in Hcy.⁹³ Inconsistent

437 results have been found for studies of folic acid and B vitamin supplementation and cognitive

438 function;^{94,95} effects may also be modified by baseline nutritional status.⁹⁶ Variation in results of clinical

439 trials may be due in part to differences in outcomes measured and follow-up time. Although these studies

440 focused on clinical outcomes, future research may leverage epigenetic aging biomarkers as surrogate 441 endpoints in clinical trials that represent intermediate changes in complex biological pathways.⁹⁷ Our 442 results support the use of some of these biomarkers to test and monitor intervention prior to disease 443 diagnosis or onset.

444 Our study was strengthened by its large sample size and population representative of middle-aged 445 and older adults in the US. We were able to analyze associations with multiple OCM-related compounds 446 and epigenetic clocks to better understand nuances in the relationships between OCM and aging-related 447 biomarkers. However, we were limited by cross-sectional data and the inability to evaluate the effects of 448 changes in OCM status on long-term epigenetic aging and health. A portion of our sample had missing 449 data on covariates and therefore our primary analyses were restricted to complete cases; however, 450 sensitivity analyses using imputed data were consistent. Additionally, we were limited by the nutritional 451 biomarker data available for NHANES. A more comprehensive study including additional OCM-related 452 micronutrients (*e.g.*, choline, betaine and B6) may provide further insights to the relationship between 453 nutrition and epigenetic aging. Our study was also unable to analyze effect modification by genetic 454 factors that affect OCM, such as variants in methylenetetrahydrofolate reductase (*MTHFR*), the enzyme 455 that processes folate. Multiple testing was not conducted, and therefore some findings might be due to 456 chance. However, we focused on precision of estimates along with pre-hypothesized associations, making 457 such adjustments non-essential. Furthermore, our study was limited to a sample representative of the US 458 adult population, and therefore findings may not be generalizable to populations with different dietary 459 habits, nutritional status, lifestyle habits, and ages.

460

461 **Conclusion**

462 As the application of epigenic aging biomarkers becomes more common in research and clinical 463 settings, it is important to understand how intervenable factors, such as nutrition, influence epigenetic 464 aging. In this study of a nationally representative sample of middle-aged and older adults, we found that 465 Hcy concentration is positively associated with epigenetic aging measured by GrimAge2 and

480 website.

481 **References**

- 483 1. Lionaki E, Ploumi C, Tavernarakis N. One-carbon metabolism: pulling the strings behind aging and neurodegeneration. Cells 2022; 11:214.
- 485 2. Paul L, Selhub J. Interaction between excess folate and low vitamin B12 status. Molecular 486 Aspects of Medicine 2017; 53:43–7.
- 487 3. Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metab 488 2017; 25:27–42.
- 489 4. Scott JM, Weir DG. Folic acid, homocysteine and one-carbon metabolism: a review of the 490 essential biochemistry. J Cardiovasc Risk 1998; 5:223–7.
- 491 5. Bozack AK, Saxena R, Gamble MV. Nutritional influences on one-carbon metabolism: 492 Effects on arsenic methylation and toxicity. Annu Rev Nutr 2018; 38:401–29.
- 493 6. Tejero J, Lazure F, Gomes A. Methylmalonic acid in aging and disease. Trends Endocrinol 494 Metab 2024; 35:188–200.
- 495 7. Office of Dietary Supplements Folate [Internet]. [cited 2024 Dec 2]; Available from: 496 https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/
- 497 8. Office of Dietary Supplements Vitamin B12 [Internet]. [cited 2024 Dec 2]; Available 498 from: https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
- 499 9. Araújo JR, Martel F, Borges N, Araújo JM, Keating E. Folates and aging: role in mild 500 cognitive impairment, dementia and depression. Ageing Research Reviews 2015; 22:9–19.
- 501 10. Clarke R, Grimley Evans J, Schneede J, Nexo E, Bates C, Fletcher A, Prentice A, Johnston 502 C, Ueland PM, Refsum H, et al. Vitamin B12 and folate deficiency in later life. Age Ageing 503 2004; 33:34–41.
- 504 11. Hazra A, Selhub J, Chao W-H, Ueland P, Hunter, Baron J. Uracil misincorporation into 505 DNA and folic acid supplementation. Am J Clin Nutr 2010; 91:160–5.
- 506 12. Reynolds E. Folic acid, ageing, depression, and dementia. BMJ 2002; 324:1512–5.
- 507 13. O'Connor DMA, Scarlett S, De Looze C, O'Halloran AM, Laird E, Molloy AM, Clarke R, 508 McGarrigle CA, Kenny RA. Low folate predicts accelerated cognitive decline: 8-year 509 follow-up of 3140 older adults in Ireland. Eur J Clin Nutr 2022; 76:950–7.
- 510 14. Bailey LB, Stover PJ, McNulty H, Fenech MF, Gregory JF, Mills JL, Pfeiffer CM, Fazili Z, 511 Zhang M, Ueland PM, et al. Biomarkers of nutrition for development—folate review. The 512 Journal of Nutrition 2015; 145:1636S-1680S.
- 513 15. He H, Shui B. Folate intake and risk of bladder cancer: a meta-analysis of epidemiological 514 studies. Int J Food Sci Nutr 2014; 65:286–92.

- 515 16. Lentz SR. Mechanisms of homocysteine□induced atherothrombosis. Journal of Thrombosis and Haemostasis 2005; 3:1646–54. and Haemostasis 2005; 3:1646–54.
- 517 17. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary 518 heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 519 83:1203–12.
- 520 18. Smith A, Refsum. Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr 521 2016; 36:211–39.
- 522 19. Zuliani G, Brombo G, Polastri M, Romagnoli T, Aarons G, Riccetti R, Seripa D, Trentini 523 A, Cervellati C. High plasma homocysteine levels predict the progression from mild 524 cognitive impairment to dementia. Neurochem Int 2024; 177:105763.
- 525 20. Zhang G, Liu S, Xu Y, Ma L-Y, Zhang W, Ji Y. Elevated plasma total homocysteine levels 526 are associated with behavioral and psychological symptoms in dementia with Lewy bodies. 527 Front Neurosci 2024; 18:1406694.
- 528 21. Xu Y, Qian X, Zhang M, Liang M. Correlations of cognitive function with serum levels of 529 homocysteine, sex hormone binding globulin, and leptin in patients with schizophrenia. Pak 530 J Med Sci 2024; 40:2319–23.
- 531 22. Unadkat SV, Padhi BK, Bhongir AV, Gandhi AP, Shamim MA, Dahiya N, Satapathy P, 532 Rustagi S, Khatib MN, Gaidhane A, et al. Association between homocysteine and coronary 533 artery disease—trend over time and across the regions: a systematic review and meta-534 analysis. The Egyptian Heart Journal 2024; 76:29.
- 535 23. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 2013; 536 14:R115.
- 537 24. Horvath S, Oshima J, Martin GM, Lu AT, Quach A, Cohen H, Felton S, Matsuyama M, 538 Lowe D, Kabacik S, et al. Epigenetic clock for skin and blood cells applied to Hutchinson 539 Gilford Progeria Syndrome and ex vivo studies. Aging 2018; 10:1758–75.
- 540 25. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, 541 Stewart JD, Li Y, et al. An epigenetic biomarker of aging for lifespan and healthspan. 542 Aging 2018; 10:573–91.
- 543 26. Lu AT, Binder AM, Zhang J, Yan Q, Reiner AP, Cox SR, Corley J, Harris SE, Kuo P-L, 544 Moore AZ, et al. DNA methylation GrimAge version 2. Aging 14:9484–549.
- 545 27. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, Hou L, Baccarelli AA, Li Y, 546 Stewart JD, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. 547 Aging 2019; 11:303–27.
- 548 28. Belsky DW, Caspi A, Arseneault L, Baccarelli A, Corcoran DL, Gao X, Hannon E, 549 Harrington HL, Rasmussen LJ, Houts R, et al. Quantification of the pace of biological

- 550 aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm. 551 eLife 2020; 9:e54870.
- 552 29. Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai P-C, Roetker NS, 553 Just AC, Demerath EW, Guan W, et al. DNA methylation-based measures of biological 554 age: meta-analysis predicting time to death. Aging 2016; 8:1844–65.
- 555 30. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of 556 ageing. Nat Rev Genet 2018; 19:371–84.
- 557 31. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, Klotzle B, Bibikova M, Fan 558 J-B, Gao Y, et al. Genome-wide methylation profiles reveal quantitative views of human 559 aging rates. Mol Cell 2013; 49:359–67.
- 560 32. Lu AT, Seeboth A, Tsai P-C, Sun D, Quach A, Reiner AP, Kooperberg C, Ferrucci L, Hou 561 L, Baccarelli AA, et al. DNA methylation-based estimator of telomere length. Aging 2019; 562 11:5895–923.
- 563 33. NHANES About the National Health and Nutrition Examination Survey [Internet]. 2024 564 [cited 2024 Nov 26]; Available from: https://www.cdc.gov/nchs/nhanes/about_nhanes.htm
- 565 34. CDC. Ethics Review Board Approval [Internet]. National Health and Nutrition 566 Examination Survey2024 [cited 2024 Dec 19]; Available from: 567 https://www.cdc.gov/nchs/nhanes/about/erb.html
- 568 35. NHANES 1999-2002 DNA Methylation Array and Epigenetic Biomarkers [Internet]. [cited 569 2024 Nov 26]; Available from: https://wwwn.cdc.gov/Nchs/Nhanes/DNAm/Default.aspx
- 570 36. Illumina. Infinium MethylationEPIC BeadChip data sheet. 2015; Available from: 571 http://www.illumina.com/content/dam/illumina-572 marketing/documents/products/datasheets/humanmethylationepic-data-sheet-1070-2015- 573 008.pdf
- 574 37. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S. 575 A beta-mixture quantile normalization method for correcting probe design bias in Illumina 576 Infinium 450 k DNA methylation data. Bioinformatics 2013; 29:189–96.
- 577 38. LAB06 [Internet]. [cited 2024 Dec 17]; Available from: 578 https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/LAB06.htm
- 579 39. L06_B [Internet]. [cited 2024 Dec 17]; Available from: 580 https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L06_B.htm
- 581 40. Rehkopf DH, Berkman LF, Coull B, Krieger N. The non-linear risk of mortality by income 582 level in a healthy population: US National Health and Nutrition Examination Survey 583 mortality follow-up cohort, 1988-2001. BMC Public Health 2008; 8:383.

618 55. Okumura K, Tsukamoto H. Folate in smokers. Clin Chim Acta 2011; 412:521–6. 619 56. Gabriel HE, Crott JW, Ghandour H, Dallal GE, Choi S-W, Keyes MK, Jang H, Liu Z, 620 Nadeau M, Johnston A, et al. Chronic cigarette smoking is associated with diminished 621 folate status, altered folate form distribution, and increased genetic damage in the buccal 622 mucosa of healthy adults. Am J Clin Nutr 2006; 83:835–41. 623 57. Hirata A. Is renal function the key to disease risk management in elevated homocysteine 624 levels? Hypertens Res 2024; 47:1976–7. 625 58. Wang A, Yeung LF, Ríos Burrows N, Rose CE, Fazili Z, Pfeiffer CM, Crider KS. Reduced 626 Kidney Function Is Associated with Increasing Red Blood Cell Folate Concentration and 627 Changes in Folate Form Distributions (NHANES 2011–2018). Nutrients 2022; 14:1054. 628 59. Thabet RH, Alessa REM, Al-Smadi ZKK, Alshatnawi BSG, Amayreh BMI, Al-Dwaaghreh 629 RBA, Salah SKA. Folic acid: friend or foe in cancer therapy. J Int Med Res 2024; 630 52:03000605231223064. 631 60. Morris M, Evans D, Bienias J, Tangney C, Hebert L, Scherr P, Schneider J. Dietary folate 632 and vitamin B12 intake and cognitive decline among community-dwelling older persons. 633 Arch Neurol 2005; 62:641–5. 634 61. Kim Y-I. Folate and cancer: a tale of Dr. Jekyll and Mr. Hyde? Am J Clin Nutr 2018; 635 107:139–42. 636 62. Arendt JFH, Sørensen HT, Horsfall LJ, Petersen I. Elevated vitamin B12 levels and dancer 637 risk in UK primary care: a THIN Database cohort study. Cancer Epidemiol Biomarkers 638 Prev 2019; 28:814–21. 639 63. Arendt JFH, Farkas DK, Pedersen L, Nexo E, Sørensen HT. Elevated plasma vitamin B12 640 levels and cancer prognosis: a population-based cohort study. Cancer Epidemiol 2016; 641 40:158–65. 642 64. Son P, Lewis L. Hyperhomocysteinemia [Internet]. In: StatPearls. Treasure Island (FL): 643 StatPearls Publishing; 2024 [cited 2024 Dec 2]. Available from: 644 http://www.ncbi.nlm.nih.gov/books/NBK554408/ 645 65. Buuren S van, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations 646 in R. Journal of Statistical Software 2011; 45:1–67. 647 66. R Core Team. R: a language and environment for statistical computing [Internet]. Vienna, 648 Austria: R Foundation for Statistical Computing; 2015. Available from: https://www.r-649 project.org/ 650 67. Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E, 651 Wirfält E, Åkesson A, et al. Strengthening the Reporting of Observational Studies in 652 Epidemiology-Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE 653 Statement. PLoS Med 2016; 13:e1002036.

- 725 92. Wang Y, Jin Y, Wang Y, Li L, Liao Y, Zhang Y, Yu D. The effect of folic acid in patients 726 with cardiovascular disease: a systematic review and meta-analysis. Medicine 2019; 727 98:e17095.
- 728 93. Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. Folic acid supplementation and the risk 729 of cardiovascular diseases: a meta□analysis of randomized controlled trials. J Am Heart 730 Assoc 2016; 5:e003768. Assoc 2016; 5:e003768.
- 731 94. Durga J, van Boxtel MPJ, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P. Effect of 732 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a 733 randomised, double blind, controlled trial. Lancet 2007; 369:208–16.
- 734 95. Ford AH, Flicker L, Alfonso H, Thomas J, Clarnette R, Martins R, Almeida OP. Vitamins 735 B12, B6, and folic acid for cognition in older men. Neurology 2010; 75:1540–7.
- 736 96. van Soest APM, van de Rest O, Witkamp RF, de Groot LCPGM. Positive effects of folic 737 acid supplementation on cognitive aging are dependent on ω-3 fatty acid status: a post hoc analysis of the FACIT trial. Am J Clin Nutr 2021; 113:801–9.
- 739 97. Biomarkers of Aging Consortium, Herzog CMS, Goeminne LJE, Poganik JR, Barzilai N, 740 Belsky DW, Betts-LaCroix J, Chen BH, Chen M, Cohen AA, et al. Challenges and 741 recommendations for the translation of biomarkers of aging. Nat Aging 2024; 4:1372–83.
- 742

744 **Tables**

745 Table 1: Participant characteristics $(N = 2,346)$.

747

750 **Table 2: Associations of serum folate, red blood cell (RBC) folate, and homocysteine with**

751 **GrimAge2 components and measured proteins.** Effect estimates (95% confidence intervals (CIs)) and *p*-values are shown for a doubling in homocysteine concentration. GrimAge2 components are expressed

on a Z-score scale. Results are from weighted generalized linear regression models adjusted for age, age² on a Z-score scale. Results are from weighted generalized linear regression models adjusted for age, age², 754 sex, race and ethnicity, BMI, smoking status, alcohol intake, education level, occupation, and poverty to income ratio

756

a. $N = 1,832$ for GrimAge2 components; $N = 1,812$ for B2M concentration; $N = 1,816$ for cystatin C concentration; $N = 1,832$ for CRP concentration; $N = 1,832$ for hemoglobin A1C concentration. b. $N = 1,830$ for GrimAge2 components; $N = 1,813$ for B2M concentration; $N = 1,815$ for cystatin C concentration; $N = 1,830$ for CRP concentration; $N = 1,830$ for hemoglobin A1C concentration. c. $N = 1,830$ for GrimAge2 components; $N = 1,812$ for B2M concentration; $N = 1,816$ for cystatin C concentration; $N = 1,830$ for CRP concentration; $N = 1,830$ for hemoglobin A1C concentration. d. log₂(serum B2M in mg/L). e. log₂(serum cystatin C in mg/L). f. log₂(CRP in mg/dL). g. log₂(plasma hemoglobin A1C %).

758 **Figure legends**

759

Figure 1: One-carbon metabolism. Compounds included in this study are shown in orange.

761

Figure 2: Associations of promoters of one-carbon metabolism (OCM) with epigenetic aging biomarkers. Effect estimates (95% confidence intervals (CIs)) and *p*-values are shown for a double

biomarkers. Effect estimates (95% confidence intervals (CIs)) and *p*-values are shown for a doubling in

764 concentration of each compound. Results are from weighted generalized linear regression models
765 adjusted for age, age², sex, race and ethnicity, BMI, education level, occupation, and poverty to in adjusted for age, age², sex, race and ethnicity, BMI, education level, occupation, and poverty to income

766 ratio. Effect estimates for Horvath1, Horvath2, Hannum, PhenoAge, and GrimAge2 EAD are in years;

767 effect estimates for DunedinPoAm are in standard deviations; and effect estimates for DNAmTL EAD are
768 in kilobases. RBC = red blood cell; EAD = epigenetic age deviation. * $p < 0.05$; ** $p < 0.01$; *** $p <$ in kilobases. RBC = red blood cell; EAD = epigenetic age deviation. * $p < 0.05$; ** $p < 0.01$; *** $p <$

- 769 0.001.
- 770

771 **Figure 3: Associations of markers of one-carbon metabolism (OCM) deficiencies with epigenetic**

aging biomarkers. Effect estimates (95% confidence intervals (CIs)) and *p*-values are shown for a

773 doubling in concentration of each OCM-related compound. Results are from weighted generalized linear
774 regression models adjusted for age, age², sex, race and ethnicity, BMI, education level, occupation, and

regression models adjusted for age, age², sex, race and ethnicity, BMI, education level, occupation, and

T15 poverty to income ratio. Effect estimates for Horvath1, Horvath2, Hannum, PhenoAge, and GrimAge2

775 poverty to income ratio. Effect estimates for Horvath1, Horvath2, Hannum, PhenoAge, and GrimAge2
776 EAD are in years; effect estimates for DunedinPoAm are in standard deviations; and effect estimates for

EAD are in years; effect estimates for DunedinPoAm are in standard deviations; and effect estimates for

- 777 DNAmTL EAD are in kilobases. EAD = epigenetic age deviation; MMA = methylmalonic acid. * $p <$ 778 0.05; ** $p < 0.01$; *** $p < 0.001$. 0.05; ** $p < 0.01$; *** $p < 0.001$.
- 779

780 **Figure 4: Scatter plots and associations of homocysteine concentration with GrimAge2 epigenetic**

781 **age deviation (EAD).** The transparency of points corresponds to their survey weights. Estimates are from
782 weighted generalized linear regression models and shown for average age, BMI, alcohol intake, and

782 weighted generalized linear regression models and shown for average age, BMI, alcohol intake, and
783 poverty to income ratio, and for the reference level of race and ethnicity, education level, and occupa poverty to income ratio, and for the reference level of race and ethnicity, education level, and occupation.

- 784 Interaction p-value for never smokers vs. former smokers = 0.27 . * $p < 0.05$; ** $p < 0.01$.
- 785

Adjusted for smoking status and alcohol intake

 $0.13(-0.32, 0.58)$

 $0.16(-0.24, 0.56)$

 0.34 (-0.23, 0.90)

 $0.52(-0.18, 1.21)$

 -0.04 $(-0.69, 0.62)$

 $-0.06(-0.18, 0.06)$

 $0.00 (-0.02, 0.01)$

